Thinly traded micro cap Harpoon Therapeutics (HARP +8.6%) is up average volume in reaction to its announcement that the first patient has been dosed in a Phase 1/2 clinical trial evaluating candidate HPN217 in patients with relapsed/refractory multiple myeloma.
The estimated primary completion date is January 2024.
The action triggers a $50M milestone payment from license option holder AbbVie (ABBV +0.9%).
The company says HPN217 is a novel tri-specific T
cell-activating construct engineered to re-direct T cells to kill B cell
maturation antigen (BCMA)-positive cancer cells.
https://seekingalpha.com/news/3564719-harpoon-therapeutics-up-9-on-launch-of-hpn217-study-in-multiple-myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.